Alpha -Tocopherol Acetate Dl- Ascorbic Acid Cyanoc
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Alpha -Tocopherol Acetate Dl- Ascorbic Acid Cyanoc
- Multivitamin + Fluoride Combination: Insufficient Data for Repurposing Evaluation
Multivitamin + Fluoride Combination: Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This candidate is a multi-component vitamin and mineral supplement containing eleven active ingredients (Vitamins A, B1, B2, B3, B6, B9, B12, C, D, E, and Sodium Fluoride), commonly used as a nutritional supplement or preventive micronutrient formula. The TxGNN model returned no predicted new indications for this combination, and no supporting clinical trials or literature were identified. As a result, a repurposing evaluation cannot be conducted at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in US; indication unknown |
| Predicted New Indication | None (no TxGNN output) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only (no output) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction was generated for this drug combination, so a mechanism-based rationale for repurposing cannot be presented.
From a pharmacological standpoint, this is a fixed-dose multivitamin and fluoride combination. The individual components (fat-soluble vitamins A, D, E; water-soluble B-complex vitamins; ascorbic acid; and sodium fluoride) collectively support basic metabolic functions, immune homeostasis, neurological integrity, bone mineralisation, and antioxidant defence. Such combinations are typically positioned as nutritional supplements rather than disease-modifying agents, which may explain the absence of TxGNN output — the model is optimised for disease–drug interactions rather than nutritional adequacy endpoints.
Additionally, the absence of a DrugBank ID for this specific combination limits automated mechanism retrieval. Individual components do have well-characterised DrugBank entries, but the composite formulation is not recognised as a single entity in the knowledge graph.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
This drug combination has no recorded NDA licenses in the Evidence Pack. The US market status is listed as Not marketed (未上市) with zero authorisations on record.
Safety Considerations
Please refer to the package insert for safety information.
Note: All safety fields (key warnings, contraindications, drug–drug interactions) returned no data in the current Evidence Pack. Given that this is a multi-component formulation, individual component safety profiles should be reviewed separately through DrugBank and the relevant prescribing information before any clinical decision is made.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline produced no predicted indications for this multi-vitamin and fluoride combination, making it impossible to identify a repurposing opportunity or assess supporting evidence. The combination is not registered in the US market and has no retrievable safety profile in this Evidence Pack.
To proceed, the following is needed:
- Resolve the drug identity issue: the combination entry lacks a DrugBank ID. Each constituent (e.g., Vitamin A → DB00162, Cyanocobalamin → DB00115) should be mapped individually and the TxGNN pipeline re-run per component or as a reformulated query.
- Obtain the original product label (package insert) to establish the intended indication and dosing context.
- Clarify the clinical question: if the intent is to evaluate a specific component (e.g., Folic Acid for neural tube defect prevention beyond its supplement label, or Vitamin D for immune-modulation), a targeted single-drug Evidence Pack should be generated.
- Once individual components are mapped, consolidate DDI data from DrugBank for the composite formulation, paying particular attention to Sodium Fluoride interactions and fat-soluble vitamin toxicity thresholds (Vitamins A and D).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.